AzPA Pharmacy Flash

• FDA approves second gene therapy for hemophilia B
  The U.S. Food and Drug Administration has approved the gene therapy fidanacogene elaparvovec for adults with hemophilia B, a rare bleeding disorder that affects almost 4 in 100,000 U.S. men. Patients are eligible for a one-time infusion of Pfizer's gene therapy if they are currently using clotting factor IX prophylaxis therapy; have current or historical […]
• Diabetes drug shows promise for the treatment of acute heart failure
  A multi center study has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death. The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious […]
• Prescription digital therapeutics for mental health: Effectiveness, challenges and future trends
  In an interview with Pharmacy Times, Kari Franson, PharmD, PhD, BCPP, Senior Associate Dean for Academic and Student Affairs & Professor of Clinical Pharmacy, USC Mann discussed her presentation at the 2024 American Association of Psychiatric Conference.